18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Patients with a biopsy diagnosis of ductal carcinoma in situ (DCIS) might be diagnosed with invasive breast cancer at excision, a phenomenon known as underestimation. Patients with DCIS are treated based on the risk of underestimation or progression to invasive cancer. The aim of our study was to expand the knowledge on underestimation and to develop a prediction model.

          Methods

          Population-based data were retrieved from the Dutch Pathology Registry and the Netherlands Cancer Registry for DCIS between January 2011 and June 2012.

          Results

          Of 2892 DCIS biopsies, 21% were underestimated invasive breast cancers. In multivariable analysis, risk factors were high-grade DCIS (odds ratio (OR) 1.43, 95% confidence interval (CI): 1.05–1.95), a palpable tumour (OR 2.22, 95% CI: 1.76–2.81), a BI-RADS (Breast Imaging Reporting and Data System) score 5 (OR 2.36, 95% CI: 1.80–3.09) and a suspected invasive component at biopsy (OR 3.84, 95% CI: 2.69–5.46). The predicted risk for underestimation ranged from 9.5 to 80.2%, with a median of 14.7%. Of the 596 invasive cancers, 39% had unfavourable features.

          Conclusions

          The risk for an underestimated diagnosis of invasive breast cancer after a biopsy diagnosis of DCIS is considerable. With our prediction model, the individual risk of underestimation can be calculated based on routinely available preoperatively known risk factors ( https://www.evidencio.com/models/show/1074).

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive

          Since 1991, a nationwide histopathology and cytopathology network and archive is in operation in The Netherlands under the name PALGA, encompassing all sixty-four pathology laboratories in The Netherlands. The overall system comprises decentralized systems at the participating laboratories, a central databank, and a dedicated communication and information exchange tool. Excerpts of all histopathology and cytopathology reports are generated automatically at the participating laboratories and transferred to the central databank. Both the decentralized systems and the central system perform checks on the quality and completeness of excerpts. Currently, about 42 million records on almost 10 million patients are stored in the central databank. Each excerpt contains patient identifiers, including demographic data and the so-called PALGA diagnosis. The latter is structured along five classification axes: topography, morphology, function, procedure, and diseases. All data transfer and communication occurs electronically with encryption of patient and laboratory identifiers. All excerpts are continuously available to all participating pathology laboratories, thus contributing to the quality of daily patient care. In addition, external parties may obtain permission to use data from the PALGA system, either on an ongoing basis or on the basis of a specific permission. Annually, 40 to 60 applications for permission to use PALGA data are submitted. Among external users are the Dutch cancer registry, population-based screening programs for cancer of the uterine cervix and breast cancer in The Netherlands, and individual investigators addressing a range of research questions. Many scientific papers and theses incorporating PALGA data have been published already. In conclusion, the PALGA system is a unique system that requires a minimal effort on the part of the participating laboratories, while providing them a powerful tool in their daily practices.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.

            To perform a meta-analysis to report pooled estimates for underestimation of invasive breast cancer (where core-needle biopsy [CNB] shows ductal carcinoma in situ [DCIS] and excision histologic examination shows invasive breast cancer) and to identify preoperative variables that predict invasive breast cancer. Studies were identified by searching MEDLINE and were included if they provided data on DCIS underestimates (overall and according to preoperative variables). Study-specific and pooled percentages for DCIS underestimates were calculated. By using meta-regression (random effects logistic modeling) the association between each study-level preoperative variable and understaged invasive breast cancer was investigated. Fifty-two studies that included 7350 cases of DCIS with findings at excision histologic examination as the reference standard met the eligibility criteria and were included. There were 1736 underestimates (invasive breast cancer at excision); the random-effects pooled estimate was 25.9% (95% confidence interval: 22.5%, 29.5%). Preoperative variables that showed significant univariate association with higher underestimation included the use of a 14-gauge automated device (vs 11-gauge vacuum-assisted biopsy, P = .006), high-grade lesion at CNB (vs non-high grade lesion, P < .001), lesion size larger than 20 mm at imaging (vs lesions ≤ 20 mm, P < .001), Breast Imaging Reporting and Data System (BI-RADS) score of 4 or 5 (vs BI-RADS score of 3, P for trend = .005), mammographic mass (vs calcification only, P < .001), and palpability (P < .001). About one in four DCIS diagnoses at CNB represent understaged invasive breast cancer. Preoperative variables significantly associated with understaging include biopsy device and guidance method, size, grade, mammographic features, and palpability.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.

              The current debate on overdiagnosis and overtreatment of screen-detected ductal carcinoma in situ (DCIS) urges the need for prospective studies to address this issue. A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns non- to slow-growing low-grade DCIS. The LORD study aims to evaluate the safety of active surveillance in women with low-risk DCIS.
                Bookmark

                Author and article information

                Contributors
                +031 78 6542100 , pwestenend@paldordrecht.nl
                Journal
                Br J Cancer
                Br. J. Cancer
                British Journal of Cancer
                Nature Publishing Group UK (London )
                0007-0920
                1532-1827
                17 October 2018
                30 October 2018
                : 119
                : 9
                : 1155-1162
                Affiliations
                [1 ]CMAnalyzing, Gounodstraat 16, 6904 HC Zevenaar, The Netherlands
                [2 ]ISNI 000000040459992X, GRID grid.5645.2, Department of Biostatistics, , Erasmus MC, University Medical Center Rotterdam, ; Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
                [3 ]ISNI 0000 0004 0396 792X, GRID grid.413972.a, Department of Surgery, , Albert Schweitzer Hospital, ; PO Box 444, 3300 AK Dordrecht, The Netherlands
                [4 ]ISNI 0000 0004 0396 792X, GRID grid.413972.a, Department of Radiology, , Albert Schweitzer Hospital, ; PO Box 444, 3300 AK Dordrecht, The Netherlands
                [5 ]ISNI 0000 0004 0501 9982, GRID grid.470266.1, Department of Research, , Netherlands Comprehensive Cancer Organisation, ; PO Box 19079, 3501 DB Utrecht, The Netherlands
                [6 ]Laboratory of Pathology Dordrecht, Karel Lotsyweg 145, 3318 AL Dordrecht, The Netherlands
                [7 ]Regional screening organization South West the Netherlands, Maasstadweg 12, 3079 DZ Rotterdam, The Netherlands
                Article
                276
                10.1038/s41416-018-0276-6
                6219477
                30327564
                302b491e-4ce1-4479-aec5-1f757d792dab
                © Cancer Research UK 2018

                This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

                History
                : 6 April 2018
                : 4 September 2018
                : 6 September 2018
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100004622, KWF Kankerbestrijding (Dutch Cancer Society);
                Award ID: SLP2015-7769
                Award Recipient :
                Categories
                Article
                Custom metadata
                © Cancer Research UK 2018

                Oncology & Radiotherapy
                risk factors,interleukins
                Oncology & Radiotherapy
                risk factors, interleukins

                Comments

                Comment on this article

                scite_

                Similar content269

                Cited by16

                Most referenced authors324